Panelists discuss how patients experiencing a high treatment burden with frequent anti-VEGF injections every 4-8 weeks are optimal candidates for the port delivery system, which can help reduce their number of clinic visits while maintaining therapeutic effectiveness.

Panelists discuss how the port delivery system (PDS) with ranibizumab represents a paradigm shift in neovascular AMD treatment by utilizing a surgically implanted refillable device that provides continuous medication delivery for 6 months, offering patients a preferred alternative to frequent intravitreal injections while ensuring consistent therapeutic levels.

The transferrin vectorised therapy is being investigated for use in patients with dry age-related macular degeneration and geographic atrophy

The company, which has European headquarters in Basel, Switzerland, plans to use the funds for a non-interventional, observational study and a first-in-human clinical trial

The laser integrates into the Corneal Refractive Workflow alongside the Visumax 800 and SMILE pro software

The commercialisation agreement for the biosimilar to aflibercept (Eylea) covers Israel and major parts of Europe, excluding Italy

The launch follows a CE Mark received in late 2024

The study built on previous research indicating specific retinal variables can serve as disease-related biomarkers in neurodegenerative diseases

Panelists discuss how aflibercept 8 mg demonstrates improved durability and maintenance of visual gains compared with 2-mg dosing, potentially reducing treatment burden while maintaining a similar safety profile.

The authors investigated systemic adverse events associated with commercial mydriatics administered during retinopathy of prematurity (ROP) screening

ViGeneron, based in Munich, also received approval for dose escalation in the ongoing phase 1b clinical trial

Clinicians need to better understand how to reduce the growth of antibiotic-resistant, more virulent bacteria, the authors said

Investigators reported that the trial demonstrated significant improvements in visual function and retinal structure for patients with optic neuritis

In October, Oxular began a phase 2 trial for its therapeutic candidate OXU-001, for treatment of diabetic macular oedema

Patients with fibromyalgia experienced changes in the macular ganglion cell layer and retinal nerve fiber layer

Panelists discuss how treat-and-extend dosing with aflibercept 2 mg allows for individualized treatment intervals while maintaining vision gains. However, optimal extension timing must be carefully determined based on disease activity markers.